Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1993713 | 0.98 | HTR2C (0.33) | HTR2CDRD4PDCD1CD274MCHR1 | |
| SCHEMBL29837287 | 0.87 | — | — | |
| SCHEMBL3516499 | 0.86 | HTR2C (0.39) | HTR2CDRD4HTR2A | |
| SCHEMBL11517457 | 0.85 | HTR2C (0.34) | HTR2CDRD4HTR2A | |
| Hydrochloric Acid SCHEMBL1995042 | 0.83 | HTR2C (0.33) | HTR2CDRD4 | |
| SCHEMBL31651687 | 0.82 | — | — | |
| SCHEMBL16788741 | 0.77 | HTR2C (0.32) | HTR2C | |
| Hydrochloric Acid SCHEMBL18953822 | 0.76 | CPB2 (0.40) | HTR2C | |
| SCHEMBL21363443 | 0.75 | SRC (0.38) | HTR2C | |
| SCHEMBL13506399 | 0.74 | MEN1 (0.39) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925702-B | Purification method of imidazo [4,5-C ] pyridine derivative and imidazo [4,5-C ] pyridine derivative | 江西凌富生物科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-115925702-A | Method for purifying imidazo [4,5-C ] pyridine derivative and imidazo [4,5-C ] pyridine derivative | 江西凌富生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-110950886-A | Method for synthesizing 1-methyl-imidazole-2-methyl formate derivative | 苏州莱克施德药业有限公司 | 2020-04-03 | — | — | CN | claimed |
| EP-4735430-A1 | MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260034126-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-8404674-B2 | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100311721-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-2134723-A1 | 9H- PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | Boehringer Ingelheim International GmbH (DE) | 2009-12-23 | — | — | EP | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2041132-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008107444-A1 | 9H- PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008003766-A2 | 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| US-4223146-A | ANTIULCER AGENTS | FARMITALIA CARLO ERBA S.P.A. (IT) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311721-A1 | COMPOUNDS | CCNA1, MKI67, CCNT1 | HTR2C 2726/4885DRD4 1448/4885PDCD1 787/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | HTR2C 2665/4885DRD4 2634/4885PDCD1 3/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | HTR2C 2942/4885DRD4 3254/4885PDCD1 157/4885 |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | IL2, IL4, NFATC1 | HTR2C 914/4885DRD4 3040/4885PDCD1 167/4885 |
| US-20260034126-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 3074/4885DRD4 3850/4885PDCD1 3233/4885 |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | HTR2C 2699/4885DRD4 3751/4885PDCD1 4471/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | HTR2C 4654/4885DRD4 4536/4885PDCD1 2899/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2C 4063/4885DRD4 2655/4885PDCD1 2508/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | HTR2C 1296/4885DRD4 660/4885PDCD1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.